CNBX Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is September - August.

Millions USD. Fiscal year is Sep - Aug.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Nov '25 Nov 30, 2025	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022	Aug '21 Aug 31, 2021	2020 - 2016
Net Income	-0.39	-0.31	-0.7	-3.71	-3.72	-3.19	Upgrade
Depreciation & Amortization	-	-	0.07	0.16	0.2	0.22	Upgrade
Loss (Gain) From Sale of Investments	-	-	0.09	2.73	-0.01	-0.2	Upgrade
Stock-Based Compensation	-	-	0.14	0.18	0.73	0.03	Upgrade
Other Operating Activities	0.08	0.04	0.02	0.05	0.72	0.71	Upgrade
Change in Accounts Receivable	0	0	0.09	-0.01	0.12	-0.01	Upgrade
Change in Accounts Payable	0.13	0.1	0.04	0.49	0.28	-0.05	Upgrade
Operating Cash Flow	-0.18	-0.17	-0.24	-0.11	-1.68	-2.49	Upgrade
Capital Expenditures	-	-	-0	-	-0	-0	Upgrade
Sale of Property, Plant & Equipment	-	-	0.11	-	0.03	-	Upgrade
Investment in Securities	-	-	-	0.02	-	0.65	Upgrade
Investing Cash Flow	-	-	0.11	0.02	0.03	0.65	Upgrade
Short-Term Debt Issued	-	0.16	0.03	0.1	0.39	2.46	Upgrade
Total Debt Issued	0.17	0.16	0.03	0.1	0.39	2.46	Upgrade
Net Debt Issued (Repaid)	0.17	0.16	0.03	0.1	0.39	2.46	Upgrade
Financing Cash Flow	0.17	0.16	0.03	0.1	0.39	2.46	Upgrade
Foreign Exchange Rate Adjustments	-	-	-	-	-0	-	Upgrade
Net Cash Flow	-0.01	-0.01	-0.1	0.01	-1.27	0.61	Upgrade
Free Cash Flow	-0.18	-0.17	-0.25	-0.11	-1.68	-2.49	Upgrade
Free Cash Flow Margin	-	-	-188.71%	-27.43%	-5610.68%	-	Upgrade
Free Cash Flow Per Share	-0.00	-0.00	-0.01	-0.01	-1.38	-2.16	Upgrade
Levered Free Cash Flow	-0.11	-0.09	-0.03	0.23	-0.51	-1.48	Upgrade
Unlevered Free Cash Flow	-0.06	-0.07	-0.02	0.23	-0.51	-1.48	Upgrade
Change in Working Capital	0.13	0.1	0.13	0.47	0.41	-0.06	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.